risperidone has been researched along with Acute Confusional Senile Dementia in 126 studies
Risperidone: A selective blocker of DOPAMINE D2 RECEPTORS and SEROTONIN 5-HT2 RECEPTORS that acts as an atypical antipsychotic agent. It has been shown to improve both positive and negative symptoms in the treatment of SCHIZOPHRENIA.
risperidone : A member of the class of pyridopyrimidines that is 2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one carrying an additional 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl group at position 2.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To examine the effects of galantamine and risperidone on agitation in patients with dementia." | 9.19 | Galantamine versus risperidone for agitation in people with dementia: a randomized, twelve-week, single-center study. ( Aarsland, D; Auestad, B; Bloniecki, V; Freund-Levi, Y; Lärksäter, M; Tysen Bäckström, AC, 2014) |
| "Elderly patients with a Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition diagnosis of Alzheimer disease and significant behavioral disturbances were randomized to receive, for a period of 8 weeks, a flexible dose of either topiramate (25-50 mg/d) or risperidone (0." | 9.14 | Comparison of topiramate and risperidone for the treatment of behavioral disturbances of patients with Alzheimer disease: a double-blind, randomized clinical trial. ( Mowla, A; Pani, A, 2010) |
| "The objective of this study was to evaluate efficacy and safety of low-dose risperidone for treating psychosis of Alzheimer disease (AD)." | 9.12 | Risperidone in the treatment of psychosis of Alzheimer disease: results from a prospective clinical trial. ( Caers, I; Gharabawi, G; Greenspan, A; Kushner, S; Mintzer, J; Schneider, LS; Van Hove, I; Weiner, M, 2006) |
| "To examine the effect of risperidone on specific behavioral and psychological symptoms of dementia (BPSD)." | 9.11 | Behavioral and psychological symptoms in patients with dementia as a target for pharmacotherapy with risperidone. ( Brodaty, H; Davidson, M; De Deyn, PP; Greenspan, A; Katz, IR; Rabinowitz, J, 2004) |
| "95 mg/day) risperidone resulted in significant improvement in aggression, agitation, and psychosis associated with dementia." | 9.10 | A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia. ( Ames, D; Brodaty, H; Clarnette, R; Grossman, F; Kirwan, J; Lee, E; Lyons, B; Snowdon, J; Woodward, M, 2003) |
| "The authors studied the incidence of tardive dyskinesia in elderly institutionalized patients with dementia being treated with risperidone." | 9.09 | Low incidence of persistent tardive dyskinesia in elderly patients with dementia treated with risperidone. ( Jeste, DV; Kane, JM; Martinez, RA; Napolitano, J; Okamoto, A, 2000) |
| "Risperidone significantly improved symptoms of psychosis and aggressive behavior in patients with severe dementia." | 9.09 | Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. Risperidone Study Group. ( Brecher, M; Clyde, C; Jeste, DV; Katz, IR; Mintzer, JE; Napolitano, J, 1999) |
| "This study is a meta-analysis of patients with psychosis of AD from four large placebo-controlled clinical trials of risperidone in dementia." | 8.84 | The efficacy and safety of risperidone in the treatment of psychosis of Alzheimer's disease and mixed dementia: a meta-analysis of 4 placebo-controlled clinical trials. ( Brodaty, H; de Deyn, PP; Greenspan, A; Katz, I; Mintzer, J; Zhu, Y, 2007) |
| "To examine the effects of galantamine and risperidone on agitation in patients with dementia." | 5.19 | Galantamine versus risperidone for agitation in people with dementia: a randomized, twelve-week, single-center study. ( Aarsland, D; Auestad, B; Bloniecki, V; Freund-Levi, Y; Lärksäter, M; Tysen Bäckström, AC, 2014) |
| " The Antipsychotic Discontinuation in Alzheimer Disease (ADAD) trial addresses these issues in a randomized, double-blind, placebo-controlled, multicenter risperidone treatment and discontinuation trial." | 5.16 | The antipsychotic discontinuation in Alzheimer disease trial: clinical rationale and study design. ( Andrews, H; Colon, S; de la Pena, D; Devanand, DP; Gupta, S; Levin, B; Mintzer, J; Pelton, GH; Schimming, C; Schultz, S; Sultzer, D, 2012) |
| "Patients with Alzheimer's disease and psychosis or agitation-aggression received open-label treatment with risperidone for 16 weeks." | 5.16 | Relapse risk after discontinuation of risperidone in Alzheimer's disease. ( Andrews, HF; Colon, S; de la Pena, D; Devanand, DP; Gupta, S; Levin, B; Mintzer, J; Pelton, GH; Schimming, C; Schultz, SK; Sultzer, DL, 2012) |
| "Elderly patients with a Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition diagnosis of Alzheimer disease and significant behavioral disturbances were randomized to receive, for a period of 8 weeks, a flexible dose of either topiramate (25-50 mg/d) or risperidone (0." | 5.14 | Comparison of topiramate and risperidone for the treatment of behavioral disturbances of patients with Alzheimer disease: a double-blind, randomized clinical trial. ( Mowla, A; Pani, A, 2010) |
| "The objective of this study was to evaluate efficacy and safety of low-dose risperidone for treating psychosis of Alzheimer disease (AD)." | 5.12 | Risperidone in the treatment of psychosis of Alzheimer disease: results from a prospective clinical trial. ( Caers, I; Gharabawi, G; Greenspan, A; Kushner, S; Mintzer, J; Schneider, LS; Van Hove, I; Weiner, M, 2006) |
| "To examine the effect of risperidone on specific behavioral and psychological symptoms of dementia (BPSD)." | 5.11 | Behavioral and psychological symptoms in patients with dementia as a target for pharmacotherapy with risperidone. ( Brodaty, H; Davidson, M; De Deyn, PP; Greenspan, A; Katz, IR; Rabinowitz, J, 2004) |
| "95 mg/day) risperidone resulted in significant improvement in aggression, agitation, and psychosis associated with dementia." | 5.10 | A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia. ( Ames, D; Brodaty, H; Clarnette, R; Grossman, F; Kirwan, J; Lee, E; Lyons, B; Snowdon, J; Woodward, M, 2003) |
| "Risperidone significantly improved symptoms of psychosis and aggressive behavior in patients with severe dementia." | 5.09 | Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. Risperidone Study Group. ( Brecher, M; Clyde, C; Jeste, DV; Katz, IR; Mintzer, JE; Napolitano, J, 1999) |
| "The authors studied the incidence of tardive dyskinesia in elderly institutionalized patients with dementia being treated with risperidone." | 5.09 | Low incidence of persistent tardive dyskinesia in elderly patients with dementia treated with risperidone. ( Jeste, DV; Kane, JM; Martinez, RA; Napolitano, J; Okamoto, A, 2000) |
| "This study is a meta-analysis of patients with psychosis of AD from four large placebo-controlled clinical trials of risperidone in dementia." | 4.84 | The efficacy and safety of risperidone in the treatment of psychosis of Alzheimer's disease and mixed dementia: a meta-analysis of 4 placebo-controlled clinical trials. ( Brodaty, H; de Deyn, PP; Greenspan, A; Katz, I; Mintzer, J; Zhu, Y, 2007) |
| " There was a significant improvement in aggression with risperidone and olanzapine treatment compared to placebo." | 4.83 | The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer's disease. ( Ballard, C; Waite, J, 2006) |
| "Advances in the assessment of the behavioral and psychological symptoms of dementia (BPSD) have been employed in large-scale clinical trials of new antipsychotic medications such as risperidone." | 4.81 | Scales to assess efficacy and safety of pharmacologic agents in the treatment of behavioral and psychological symptoms of dementia. ( De Deyn, PP; Wirshing, WC, 2001) |
| "Patients with severe baseline hallucinations were more likely to relapse after randomization, and the presence of baseline hallucinations was associated with a higher risk of relapse after discontinuation of risperidone compared with continued risperidone treatment." | 3.85 | Prediction of Relapse After Discontinuation of Antipsychotic Treatment in Alzheimer's Disease: The Role of Hallucinations. ( Andrews, HF; Colon, S; de la Pena, D; Devanand, DP; Gupta, S; Lee, S; Levin, B; Mintzer, J; Patel, AN; Pelton, GH; Schimming, C; Schultz, SK; Sultzer, DL, 2017) |
| " The present study investigated and confirmed significant sensitivity of the model to the aggression-lowering ability of the antipsychotic agent risperidone (CAS 106266-06-2)." | 3.74 | Validation of the APP23 transgenic mouse model of Alzheimer's disease through evaluation of risperidone treatment on aggressive behaviour. ( Coen, K; De Deyn, PP; Van Dam, D; Vloeberghs, E, 2008) |
| " Age, gender, years of education, total intracranial volume, apolipoprotein E genotype, dosage of risperidone, the baseline scores on the Korean version of the Mini-Mental State Examination, and the baseline psychotic and nonpsychotic symptoms scores on the K-NPI were measured as covariates of no interest." | 2.82 | Gray matter volumes and treatment response of psychotic symptoms to risperidone in antipsychotic-naïve Alzheimer's disease patients. ( Chung, YI; Jeong, HJ; Kim, HJ; Kim, JH; Kim, TH; Kim, YH; Lee, BD; Lee, YM; Moon, E; Mun, CW; Park, JM, 2016) |
| "CATIE-AD included 421 outpatients with Alzheimer's disease and psychosis or agitated/aggressive behavior who were randomly assigned to receive masked, flexible-dose olanzapine, quetiapine, risperidone, or placebo." | 2.76 | Cognitive effects of atypical antipsychotic medications in patients with Alzheimer's disease: outcomes from CATIE-AD. ( Dagerman, KS; Hsiao, JK; Keefe, RS; Lebowitz, BD; Lyketsos, CG; Mack, WJ; Sano, M; Schneider, LS; Stroup, TS; Sultzer, DL; Tariot, PN; Vigen, CL; Zheng, L, 2011) |
| "Antipsychotics are frequently used to treat psychosis, aggression and agitation in patients with Alzheimer's disease (AD), but safety warnings abound." | 2.76 | Escitalopram versus risperidone for the treatment of behavioral and psychotic symptoms associated with Alzheimer's disease: a randomized double-blind pilot study. ( Barak, Y; Paleacu, D; Plopski, I; Tadger, S, 2011) |
| "Risperidone has been used to treat behavioral symptoms, such as delusions and agitation, in people with Alzheimer's disease." | 2.75 | Association of 9-hydroxy risperidone concentrations with risk of switching or discontinuation in the clinical antipsychotic trial of intervention effectiveness-Alzheimer's disease trial. ( Anyama, NG; Bies, RR; Lieberman, JA; Marder, SR; Pollock, BG; Schneider, LS; Wessels, AM, 2010) |
| "Elderly patients with Alzheimer's disease are frequently treated with these antipsychotics, but limited data are available on their metabolic effects." | 2.74 | Metabolic changes associated with second-generation antipsychotic use in Alzheimer's disease patients: the CATIE-AD study. ( Dagerman, KS; Hsiao, JK; Lebowitz, BD; Lyketsos, CG; Mack, WJ; Schneider, LS; Stroup, TS; Sultzer, DL; Tariot, PN; Vigen, C; Zheng, L, 2009) |
| "Risperidone treatment was generally well tolerated, although extrapyramidal symptoms were noted in a dose-dependent manner." | 2.71 | Risperidone use in Korean patients with Alzheimer's disease: optimal dosage and effect on behavioural and psychological symptoms, cognitive function and activities of daily living. ( Choi, SK; Kim, JM; Lee, H; Shin, IS; Yoon, JS, 2003) |
| "promazine in the treatment of behavioral and psychological symptoms in dementia(BPSD)." | 2.71 | Comparison of the efficacy of new and conventional antipsychotic drugs in the treatment of behavioral and psychological symptoms of dementia (BPSD). ( Cotroneo, A; De Sarro, G; Gareri, P; Lacava, R; Loiacono, A; Marigliano, N; Seminara, G, 2004) |
| "Risperidone treatment was well tolerated, and no clinically relevant changes in EPS." | 2.70 | Effect of risperidone on behavioral and psychological symptoms and cognitive function in dementia. ( Ertl, MG; Haushofer, M; Kraxberger, E; Masching, AJ; Rainer, MK, 2001) |
| "Haloperidol-treated patients showed a worsening on Simpson-Angus scale while there was no significant change in this measure in risperidone-treated patients." | 2.70 | A double-blind randomised comparison of risperidone and haloperidol in the treatment of behavioural and psychological symptoms in Chinese dementia patients. ( Chan, WC; Chiu, HF; Choy, CN; Lam, LC; Leung, VP; Li, SW, 2001) |
| " Presence of drug in the olfactory bulb, in turn, increases the drug bioavailability in the brain and reduces the drug degradation as well as wastage of the drug through` systemic clearance." | 2.58 | Nose-to-brain drug delivery: An update on clinical challenges and progress towards approval of anti-Alzheimer drugs. ( Agrawal, M; Alexander, A; Antimisiaris, SG; Chougule, MB; Saraf, S; Shoyele, SA, 2018) |
| "Once the clinical diagnosis of Alzheimer's disease has been made, a treatment plan must be developed." | 2.41 | Guidelines for managing Alzheimer's disease: Part II. Treatment. ( Cherry, D; Cummings, JL; Frank, JC; Hewett, L; Kemp, B; Kohatsu, ND; Mittman, B, 2002) |
| "Patients with Alzheimer's disease exhibit aggressive behavior, and alterations in their serotonergic function have been identified." | 2.41 | Underlying mechanisms of psychosis and aggression in patients with Alzheimer's disease. ( Mintzer, JE, 2001) |
| "The cumulative curves of class-specific adverse events in risperidone clinical trials of schizophrenia were similar to those first reported for other atypical antipsychotic drugs." | 1.72 | Depicting Risperidone Safety Profiles in Clinical Trials Across Different Diagnoses Using a Dopamine D ( Hopkins, SC; Koblan, KS; Ogirala, A; Worden, M; Zeni, C, 2022) |
| "The Medication Use and Alzheimer's Disease (MEDALZ) cohort included 70,718 community-dwelling people with AD in Finland during 2005-2011." | 1.72 | Antipsychotic Use and Risk of Stroke Among Community-Dwelling People With Alzheimer's Disease. ( Bell, JS; Hartikainen, S; Koponen, M; Lavikainen, P; Rajamaki, B; Taipale, H; Tanskanen, A; Tolppanen, AM, 2022) |
| "People with Alzheimer's disease (AD), the most common cause of dementia, show synaptic loss and disruption of functional brain networks along with neuritic plaques and neurofibrillary tangles." | 1.72 | Neuropsychiatric Symptoms in Dementia: Considering a Clinical Role for Electroencephalography. ( Aarsland, D; Andersson, T; Berglund, A; Cummings, J; Freund-Levi, Y; Holmgren, S, 2022) |
| "25 mg/day (85 years, MMSE of 5), to 1 mg/day (75 years, MMSE of 15), with alternate day dosing required for those with slower drug clearance." | 1.62 | Towards safer risperidone prescribing in Alzheimer's disease. ( Bertrand, J; Bies, R; Bramon, E; Howard, R; Liu, KY; Otani, Y; Ozer, M; Pollock, BG; Reeves, S; Uchida, H; Yoshida, K, 2021) |
| "Thirty-three patients with paranoid schizophrenia and 18 patients with AD were included in the study." | 1.56 | [Antioxidant status in patients with paranoid schizophrenia and Alzheimer disease]. ( Grishina, NK; Khannanova, AN; Portnova, GV; Proskurnina, EV; Sokolova, SV; Sozarukova, MM, 2020) |
| "Case-crossover analysis is a potential approach for identifying candidate drugs and drug-drug interactions associated with adverse events as it implicitly controls for fixed confounders." | 1.46 | Screening approach for identifying candidate drugs and drug-drug interactions related to hip fracture risk in persons with Alzheimer disease. ( Hartikainen, S; Koponen, M; Lavikainen, P; Paananen, J; Taipale, H; Tanskanen, A; Tiihonen, J; Tolppanen, AM, 2017) |
| "Tiapride is more effective in improving clinical symptoms of senile dementia and causes fewer adverse effects." | 1.43 | Tiapride is more effective and causes fewer adverse effects than risperidone in the treatment of senile dementia. ( Huang, YJ; Lei, LF; Li, LH; Yuan, Y, 2016) |
| " Our objective was to study the duration of antipsychotic use and factors associated with long-term use (365 days or over) among community-dwelling persons with Alzheimer׳s disease (AD) during a 7-year follow-up." | 1.42 | Long-term use of antipsychotics among community-dwelling persons with Alzheimer׳s disease: A nationwide register-based study. ( Ahonen, R; Hartikainen, S; Koponen, M; Taipale, H; Tanskanen, A; Tiihonen, J; Tolppanen, AM, 2015) |
| "Severe myoclonus and increased restlessness are hallmarks of the disorder." | 1.36 | A perfect storm in the emergency department. ( Wijdicks, EF; Yee, AH, 2010) |
| "Risperidone and promazine were the most frequently prescribed antipsychotic; 40." | 1.35 | Use and misuse of antipsychotic drugs in patients with dementia in Alzheimer special care units. ( Lucca, U; Matucci, M; Nobili, A; Pasina, L; Riva, E; Tarantola, M; Tettamanti, M; Trevisan, S, 2009) |
| "4 l h(-1) and parameter estimates for risperidone half-life in PM, IM and EM were 25, 8." | 1.35 | Population pharmacokinetic analysis for risperidone using highly sparse sampling measurements from the CATIE study. ( Aravagiri, M; Bies, RR; Coley, K; Feng, Y; Kirshner, M; Marder, S; Miller, D; Pollock, BG; Schneider, L, 2008) |
| "However, patients with vascular dementia had an increased risk in hospitalization for a CVE." | 1.34 | Comparison of risk of cerebrovascular events in an elderly VA population with dementia between antipsychotic and nonantipsychotic users. ( Barnett, MJ; Perry, PJ; Wehring, H, 2007) |
| " After the first 3 days of therapy the dosage was increased to 1 mg in 2 doses (morning and evening), then a further 0." | 1.34 | Clinical experience with risperidone in the treatment of behavioral and psychological symptoms of dementia. ( Aguglia, E; Cristante, T; Onor, ML; Saina, M; Trevisiol, M, 2007) |
| " Chronic administration of the synthetic gonadotropin (luteinising hormone) releasing hormone analogue, goserelin, reduces testosterone activity." | 1.33 | Gonadotrophin-releasing hormone agonist treatment of aggression in Alzheimer's disease: a case report. ( Raskind, MA; Rosin, RA, 2005) |
| "Memantine was initiated, and the dose was titrated to 10 mg twice daily." | 1.33 | Antipsychotic dose-sparing effect with addition of memantine. ( Sleeper, RB, 2005) |
| "The authors report 2 cases, in Alzheimer's disease and vascular dementia, in which erotomania emerged in the early stage of the underlying disorder." | 1.32 | Erotomania variants in dementia. ( Brüne, M; Schröder, SG, 2003) |
| "Risperidone was highly effective and well tolerated in the treatment of behavioural disturbances in dementia under routine conditions of general practice." | 1.32 | [Treatment of behavioral disorders in dementia with risperidone in psychogeriatric out-patients]. ( Delius-Stute, H; Kurz, A; Rettig, K; Schwalen, S, 2003) |
| "Patients with vascular dementia were more likely to respond than those with Alzheimer's disease ( p = 0." | 1.31 | Shifting from haloperidol to risperidone for behavioral disturbances in dementia: safety, response predictors, and mood effects. ( Chang, WH; Chang, YC; Chiu, CC; Huang, MC; Lane, HY; Su, MH, 2002) |
| " In this case, NMS seemed to be induced by bacterial pneumonia after long term administration of LPZ 5 mg per day." | 1.30 | [A study of neuroleptic malignant syndrome in the presenium and senium]. ( Honma, H; Koyama, T; Matsubara, S; Suzuki, I; Watanabe, N, 1998) |
| "Risperidone was a useful adjunct in the treatment of agitation and psychosis in outpatients with dementia but was limited by EPS in about one-third of patients." | 1.30 | Risperidone treatment of behavioral disturbances in outpatients with dementia. ( Binetti, G; Ghaemi, SN; Gomez-Isla, T; Growdon, JH; Hyman, BT; Irizarry, MC; Lee-Cherry, ER, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 11 (8.73) | 18.2507 |
| 2000's | 73 (57.94) | 29.6817 |
| 2010's | 33 (26.19) | 24.3611 |
| 2020's | 9 (7.14) | 2.80 |
| Authors | Studies |
|---|---|
| Koponen, M | 5 |
| Rajamaki, B | 1 |
| Lavikainen, P | 4 |
| Bell, JS | 1 |
| Taipale, H | 5 |
| Tanskanen, A | 5 |
| Hartikainen, S | 5 |
| Tolppanen, AM | 5 |
| Zhu, L | 1 |
| Wu, G | 1 |
| Heng, W | 1 |
| Zang, X | 1 |
| Mühlbauer, V | 1 |
| Möhler, R | 1 |
| Dichter, MN | 1 |
| Zuidema, SU | 1 |
| Köpke, S | 1 |
| Luijendijk, HJ | 1 |
| Holmgren, S | 1 |
| Andersson, T | 1 |
| Berglund, A | 1 |
| Aarsland, D | 3 |
| Cummings, J | 2 |
| Freund-Levi, Y | 3 |
| Hopkins, SC | 1 |
| Ogirala, A | 1 |
| Zeni, C | 1 |
| Worden, M | 1 |
| Koblan, KS | 1 |
| Roughley, M | 1 |
| Mena, C | 1 |
| Howard, R | 3 |
| Reeves, S | 3 |
| Bertrand, J | 2 |
| Tiihonen, J | 4 |
| Sokolova, SV | 1 |
| Sozarukova, MM | 1 |
| Khannanova, AN | 1 |
| Grishina, NK | 1 |
| Portnova, GV | 1 |
| Proskurnina, EV | 1 |
| Uchida, H | 2 |
| Yoshida, K | 2 |
| Otani, Y | 1 |
| Ozer, M | 1 |
| Liu, KY | 1 |
| Bramon, E | 1 |
| Bies, R | 1 |
| Pollock, BG | 4 |
| Nagamine, T | 1 |
| Boccardi, V | 1 |
| Baroni, M | 1 |
| Paolacci, L | 1 |
| Ercolani, S | 1 |
| Longo, A | 1 |
| Giordano, M | 1 |
| Ruggiero, C | 1 |
| Mecocci, P | 1 |
| Lavretsky, H | 2 |
| Bahramabadi, R | 1 |
| Samadi, M | 1 |
| Vakilian, A | 1 |
| Jafari, E | 1 |
| Fathollahi, MS | 1 |
| Arababadi, MK | 1 |
| Paananen, J | 1 |
| Agrawal, M | 1 |
| Saraf, S | 2 |
| Antimisiaris, SG | 1 |
| Chougule, MB | 1 |
| Shoyele, SA | 1 |
| Alexander, A | 1 |
| Bloniecki, V | 2 |
| Auestad, B | 1 |
| Tysen Bäckström, AC | 1 |
| Lärksäter, M | 1 |
| Torres-Lista, V | 1 |
| López-Pousa, S | 1 |
| Giménez-Llort, L | 1 |
| Leibovitz, A | 1 |
| Ahonen, R | 2 |
| Yin, Y | 1 |
| Liu, Y | 1 |
| Zhuang, J | 1 |
| Pan, X | 1 |
| Li, P | 1 |
| Yang, Y | 1 |
| Li, YP | 1 |
| Zhao, ZQ | 1 |
| Huang, LQ | 1 |
| Zhao, ZX | 1 |
| Lee, YM | 1 |
| Park, JM | 1 |
| Lee, BD | 1 |
| Moon, E | 1 |
| Jeong, HJ | 1 |
| Chung, YI | 1 |
| Kim, JH | 1 |
| Kim, HJ | 1 |
| Mun, CW | 1 |
| Kim, TH | 1 |
| Kim, YH | 1 |
| Yuan, Y | 1 |
| Li, LH | 1 |
| Huang, YJ | 1 |
| Lei, LF | 1 |
| Patel, AN | 1 |
| Lee, S | 1 |
| Andrews, HF | 2 |
| Pelton, GH | 3 |
| Schultz, SK | 3 |
| Sultzer, DL | 7 |
| Mintzer, J | 6 |
| de la Pena, D | 3 |
| Gupta, S | 3 |
| Colon, S | 3 |
| Schimming, C | 3 |
| Levin, B | 3 |
| Devanand, DP | 4 |
| Wu, L | 1 |
| Feng, X | 1 |
| Li, T | 1 |
| Sun, B | 1 |
| Khan, MZ | 1 |
| He, L | 1 |
| Roberts, R | 1 |
| Suzuki, T | 1 |
| Lebowitz, B | 2 |
| Abe, T | 1 |
| Mimura, M | 1 |
| Blennow, K | 1 |
| Falahati, F | 1 |
| Winblad, B | 1 |
| Davis, SM | 2 |
| Tariot, PN | 5 |
| Dagerman, KS | 5 |
| Lebowitz, BD | 4 |
| Lyketsos, CG | 5 |
| Rosenheck, RA | 2 |
| Hsiao, JK | 5 |
| Lieberman, JA | 4 |
| Schneider, LS | 7 |
| Vloeberghs, E | 1 |
| Coen, K | 1 |
| Van Dam, D | 1 |
| De Deyn, PP | 8 |
| Feng, Y | 1 |
| Coley, K | 1 |
| Marder, S | 1 |
| Miller, D | 1 |
| Kirshner, M | 1 |
| Aravagiri, M | 1 |
| Schneider, L | 1 |
| Bies, RR | 2 |
| McNeal, KM | 1 |
| Meyer, RP | 1 |
| Lukacs, K | 1 |
| Senseney, A | 1 |
| Zheng, L | 2 |
| Mack, WJ | 2 |
| Stroup, TS | 3 |
| Vigen, C | 1 |
| Wittmann, M | 1 |
| Hausner, H | 1 |
| Hajak, G | 1 |
| Haen, E | 1 |
| Yee, AH | 1 |
| Wijdicks, EF | 1 |
| Mowla, A | 1 |
| Pani, A | 1 |
| Zand, L | 1 |
| Hoffman, SJ | 1 |
| Nyman, MA | 1 |
| Wessels, AM | 1 |
| Anyama, NG | 1 |
| Marder, SR | 1 |
| Schultz, S | 1 |
| Sultzer, D | 2 |
| Andrews, H | 1 |
| Nobili, A | 1 |
| Pasina, L | 1 |
| Trevisan, S | 1 |
| Riva, E | 1 |
| Lucca, U | 1 |
| Tettamanti, M | 1 |
| Matucci, M | 1 |
| Tarantola, M | 1 |
| Barak, Y | 1 |
| Plopski, I | 1 |
| Tadger, S | 1 |
| Paleacu, D | 1 |
| Vigen, CL | 1 |
| Keefe, RS | 1 |
| Sano, M | 1 |
| Zverova, M | 1 |
| Förstl, H | 2 |
| Gnjidic, D | 1 |
| Hilmer, SN | 1 |
| Power, GA | 1 |
| Ling, SM | 1 |
| Bonner, AF | 1 |
| McMullen, TL | 1 |
| Liu, HC | 1 |
| Lin, SK | 1 |
| Sung, SM | 1 |
| Friedman, JH | 1 |
| Fernandez, HH | 1 |
| Onalaja, D | 1 |
| Jainer, AK | 1 |
| Shamreĭ, VK | 1 |
| Kolchev, AI | 1 |
| Dobrovol'skaia, NV | 1 |
| Brodaty, H | 8 |
| Ames, D | 2 |
| Snowdon, J | 3 |
| Woodward, M | 2 |
| Kirwan, J | 2 |
| Clarnette, R | 2 |
| Lee, E | 3 |
| Lyons, B | 2 |
| Grossman, F | 2 |
| Hori, K | 1 |
| Oda, T | 1 |
| Tominaga, I | 1 |
| Inada, T | 1 |
| Edell, WS | 1 |
| Rupnow, MF | 1 |
| Hoeh, N | 1 |
| Gyulai, L | 1 |
| Weintraub, D | 2 |
| Streim, J | 1 |
| Brüne, M | 1 |
| Schröder, SG | 1 |
| Yoon, JS | 1 |
| Kim, JM | 1 |
| Lee, H | 1 |
| Shin, IS | 1 |
| Choi, SK | 1 |
| Fhager, B | 1 |
| Meiri, IM | 1 |
| Sjögren, M | 1 |
| Edman, A | 1 |
| Okamoto, A | 2 |
| Turkoz, I | 1 |
| Gharabawi, G | 2 |
| Meguro, K | 2 |
| Meguro, M | 2 |
| Tanaka, Y | 1 |
| Akanuma, K | 2 |
| Yamaguchi, K | 1 |
| Itoh, M | 1 |
| Gareri, P | 1 |
| Cotroneo, A | 1 |
| Lacava, R | 1 |
| Seminara, G | 1 |
| Marigliano, N | 1 |
| Loiacono, A | 1 |
| De Sarro, G | 1 |
| Zannino, G | 1 |
| Gargiulo, A | 1 |
| Lamenza, F | 1 |
| Marotta, MG | 1 |
| Barzotti, T | 1 |
| Silvestri, A | 1 |
| Ettorre, E | 1 |
| Marigliano, V | 1 |
| Kurz, A | 2 |
| Delius-Stute, H | 1 |
| Rettig, K | 1 |
| Schwalen, S | 1 |
| Rabinowitz, J | 3 |
| Katz, IR | 4 |
| Greenspan, A | 6 |
| Davidson, M | 2 |
| Kleinman, L | 1 |
| Frank, L | 1 |
| Ciesla, G | 1 |
| Rupnow, M | 1 |
| Martin-Cook, K | 1 |
| Hynan, LS | 1 |
| Rice-Koch, K | 1 |
| Svetlik, DA | 1 |
| Weiner, MF | 1 |
| Warner, J | 1 |
| Butler, R | 1 |
| Arya, P | 1 |
| Lacomblez, L | 1 |
| Burns, A | 1 |
| Rosin, RA | 1 |
| Raskind, MA | 1 |
| Sleeper, RB | 1 |
| Deberdt, WG | 1 |
| Dysken, MW | 1 |
| Rappaport, SA | 1 |
| Feldman, PD | 1 |
| Young, CA | 1 |
| Hay, DP | 1 |
| Lehman, DL | 1 |
| Dossenbach, M | 1 |
| Degenhardt, EK | 1 |
| Breier, A | 1 |
| Suh, GH | 1 |
| Shah, A | 1 |
| Katz, I | 3 |
| Cohen-Mansfield, J | 1 |
| Ballard, C | 1 |
| Waite, J | 1 |
| Caers, I | 1 |
| Van Hove, I | 1 |
| Kushner, S | 1 |
| Weiner, M | 1 |
| Rondanelli, M | 1 |
| Sarra, S | 1 |
| Antoniello, N | 1 |
| Mansi, V | 1 |
| Govoni, S | 1 |
| Falvo, F | 1 |
| Solerte, SB | 1 |
| Ferrari, E | 1 |
| Onor, ML | 1 |
| Saina, M | 1 |
| Trevisiol, M | 1 |
| Cristante, T | 1 |
| Aguglia, E | 1 |
| Ismail, MS | 1 |
| Ryan, JM | 1 |
| Yumru, M | 1 |
| Eren Ozen, M | 1 |
| Savas, HA | 1 |
| Selek, S | 1 |
| Madhusoodanan, S | 1 |
| Bogunovic, O | 1 |
| Lim, HK | 1 |
| Pae, CU | 1 |
| Lee, C | 1 |
| Lee, CU | 1 |
| Holmes, C | 1 |
| Wilkinson, D | 1 |
| Dean, C | 1 |
| Clare, C | 1 |
| El-Okl, M | 1 |
| Hensford, C | 1 |
| Moghul, S | 1 |
| Farver, D | 1 |
| Zhu, Y | 1 |
| Ito, T | 1 |
| Kasuya, M | 1 |
| Ishii, H | 1 |
| Mori, E | 1 |
| Harrison, BE | 1 |
| Therrien, B | 1 |
| Daiello, LA | 1 |
| Barnett, MJ | 1 |
| Wehring, H | 1 |
| Perry, PJ | 1 |
| Rocca, P | 1 |
| Marino, F | 1 |
| Montemagni, C | 1 |
| Perrone, D | 1 |
| Bogetto, F | 1 |
| Auchus, AP | 1 |
| Freeman, A | 1 |
| Green, RC | 1 |
| Jeanblanc, W | 1 |
| Davis, YB | 1 |
| Beck, BJ | 1 |
| Brecher, M | 2 |
| Fischer, P | 1 |
| Tauscher, J | 1 |
| Küfferle, B | 1 |
| Suzuki, I | 1 |
| Honma, H | 1 |
| Watanabe, N | 1 |
| Matsubara, S | 1 |
| Koyama, T | 1 |
| Magnuson, TM | 1 |
| Keller, BK | 1 |
| Burke, WJ | 1 |
| Jeste, DV | 4 |
| Mintzer, JE | 2 |
| Clyde, C | 1 |
| Napolitano, J | 2 |
| Irizarry, MC | 1 |
| Ghaemi, SN | 1 |
| Lee-Cherry, ER | 1 |
| Gomez-Isla, T | 1 |
| Binetti, G | 1 |
| Hyman, BT | 1 |
| Growdon, JH | 1 |
| Kane, JM | 1 |
| Martinez, RA | 1 |
| Kwak, YT | 1 |
| Han, IW | 1 |
| Baik, J | 1 |
| Koo, MS | 1 |
| Negrón, AE | 1 |
| Reichman, WE | 1 |
| Leslie, DL | 1 |
| Rosenheck, R | 1 |
| Wirshing, WC | 1 |
| Laks, J | 1 |
| Engelhardt, E | 1 |
| Marinho, V | 1 |
| Rozenthal, M | 1 |
| Souza, FC | 1 |
| Bacaltchuk, J | 1 |
| Stoppe, A | 1 |
| Ferreira, RC | 1 |
| Bottino, C | 1 |
| Scalco, M | 1 |
| Davis, KL | 1 |
| Davis, S | 1 |
| Olin, JT | 1 |
| Rabins, PV | 1 |
| Small, GW | 1 |
| Chan, WC | 1 |
| Lam, LC | 1 |
| Choy, CN | 1 |
| Leung, VP | 1 |
| Li, SW | 1 |
| Chiu, HF | 1 |
| Rainer, MK | 1 |
| Masching, AJ | 1 |
| Ertl, MG | 1 |
| Kraxberger, E | 1 |
| Haushofer, M | 1 |
| Lane, HY | 1 |
| Chang, YC | 1 |
| Su, MH | 1 |
| Chiu, CC | 1 |
| Huang, MC | 1 |
| Chang, WH | 1 |
| Shigenobu, K | 1 |
| Ikeda, M | 1 |
| Fukuhara, R | 1 |
| Maki, N | 1 |
| Hokoishi, K | 1 |
| Nebu, A | 1 |
| Komori, K | 1 |
| Tanabe, H | 1 |
| Cummings, JL | 1 |
| Frank, JC | 1 |
| Cherry, D | 1 |
| Kohatsu, ND | 1 |
| Kemp, B | 1 |
| Hewett, L | 1 |
| Mittman, B | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| [NCT00036114] | Phase 3 | 0 participants | Interventional | 2000-03-31 | Completed | ||
| A Single Center, Double-Blind, Placebo-Controlled Study to Examine the Safety and Efficacy of Pimavanserin for the Treatment of Psychosis in Alzheimer's Disease[NCT02035553] | Phase 2 | 181 participants (Actual) | Interventional | 2013-11-30 | Completed | ||
| Comparative Effectiveness of Antipsychotic Medications in Patients With Alzheimer's Disease (CATIE Alzheimer's Disease Trial)[NCT00015548] | 450 participants | Interventional | 2001-03-31 | Completed | |||
| Clinical Research Center for Dementia of South Korea (CREDOS)[NCT01198093] | 800 participants (Anticipated) | Observational | 2005-11-30 | Recruiting | |||
| Antipsychotic Discontinuation in Alzheimer's Disease[NCT00417482] | Phase 4 | 180 participants (Actual) | Interventional | 2004-08-31 | Completed | ||
| Population Pharmacokinetic Modeling of Qishe Pill in Three Major TCM-defined Constitutional Types of Healthy Chinese Subjects: Study Protocol for a Phase I Clinical Trial[NCT02294448] | Phase 1 | 36 participants (Anticipated) | Interventional | 2014-11-30 | Recruiting | ||
| Treatment of Psychosis and Agitation in Alzheimer's Disease[NCT02129348] | Phase 2 | 77 participants (Actual) | Interventional | 2014-06-30 | Completed | ||
| Risperidone in the Treatment of Behavioural and Psychological Signs and Symptoms in Dementia (BPSSD): a Multicentre, Double-blind, Placebo-controlled Parallel-group Trial[NCT00249158] | Phase 3 | 344 participants (Actual) | Interventional | 1998-03-31 | Completed | ||
| Efficacy And Safety Of A Flexible Dose Of Risperidone Versus Placebo In The Treatment Of Psychosis Of Alzheimer's Disease.[NCT00034762] | Phase 3 | 473 participants (Actual) | Interventional | 2000-12-31 | Completed | ||
| A Pragmatic Randomized-controlled Trial of a Multi-pronged Electronic Health Record-based Clinical Decision Support Tool to Reduce Low-value Antipsychotic Prescriptions Among Older Adults With Alzheimer's and Related Dementias[NCT04851691] | 117 participants (Anticipated) | Interventional | 2021-08-03 | Enrolling by invitation | |||
| Elderly Patients With Dementia in the Department of Acute Geriatrics: Pilot Study, Monocentric, Randomized Use of Aromatherapy as a Complementary Treatment to Psychopharmacotherapy in Psychological Disorders and BPSD Behavior[NCT03662360] | 32 participants (Actual) | Interventional | 2018-05-20 | Completed | |||
| A Randomized, Double-Blind, Placebo-Controlled Study of Risperidone for Treatment of Behavioral Disturbances in Subjects With Dementia[NCT00253123] | Phase 3 | 626 participants (Actual) | Interventional | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Change from Baseline to Day 43 in the Neuropsychiatric Inventory-Nursing Home Version (NPI-NH) psychosis score (Delusions [Domain A]+Hallucinations [Domain B]) in the Full Analysis Set (FAS). The NPI-NH is a questionnaire that quantifies behavioral changes in dementia in nursing home patients and evaluates 12 behavioral domains. For each of the 12 behavioral domains the Frequency (scale:1=occasionally to 4=very frequently) is multiplied by the Severity (scale:1=Mild to 3=Severe) to obtain a domain score (frequency x severity), The NPI-NH Psychosis Subscale consists of the two domains of Delusions and Hallucinations, calculated by adding the Individual domain scores, to yield a possible total score of 0 to 24. Lower scores correspond to less severity. A negative change score from baseline indicates improvement. (NCT02035553)
Timeframe: Day 43
| Intervention | Score on the NPI-NH scale (Least Squares Mean) |
|---|---|
| Placebo | -1.93 |
| Pimavanserin 40 mg | -3.76 |
The Abnormal Involuntary Movement Scale (AIMS) assesses signs of tardive dyskinesia, a movement disorder that can occur with prolonged use of antipsychotic medication. The AIMS score ranges from 0 to 35, with higher scores indicating more severe symptoms. For each subject, the change in AIMS score between week 16 and randomization was calculated by subtraction, so that a positive value indicates an increase in AIMS over time. (NCT00417482)
Timeframe: Phase B, weeks 1-16 (study weeks 16-32)
| Intervention | units on a scale (Mean) |
|---|---|
| Placebo | 0.03 |
| Risperidone | 0.24 |
Extrapyramidal signs, also known as Parkinsonian signs, refer to signs of tremor, rigidity, and bradykinesia (slowed movement) that are seen in Parkinson's disease. Assessment of extrapyramidal signs (EPS) were made with the use of the Simpson-Angus scale (which ranges from 1-40) with higher scores indicating more extrapyramidal signs. For each subject, the change in EPS between week 16 and baseline (randomization) was calculated by subtraction, so that a positive value indicates an increase in EPS over time. (NCT00417482)
Timeframe: Phase B, weeks 1-16 (study weeks 16-32)
| Intervention | units on a scale (Mean) |
|---|---|
| Placebo | -0.20 |
| Risperidone | 0.34 |
The MMSE assesses cognition. Scores range from 0-30, with higher scores indicating better cognition. For each subject, the change in MMSE between week 16 and baseline (randomization) was calculated by subtraction, so that a positive value indicates an increase in MMSE over time. (NCT00417482)
Timeframe: Phase B, weeks 1-16 (study weeks 16-32)
| Intervention | units on a scale (Mean) |
|---|---|
| Placebo | -0.13 |
| Risperidone | -0.77 |
Physical Self-Maintenance Scale, which ranges from 1 to 30, with higher scores indicating WORSE functioning. For each subject, the change in PSMS between week 16 and randomization was calculated by subtraction, so that a positive value indicates an increase in PSMS (worse functioning) over time. (NCT00417482)
Timeframe: Phase B, weeks 1-16 (study weeks 16-32)
| Intervention | units on a scale (Mean) |
|---|---|
| Placebo | 0.18 |
| Risperidone | 0.80 |
"A relapse occurred in Phase B (post-randomization) if both of the following criteria were met:~Increase in the Neuropsychiatric Inventory (NPI) core score of 30% or more OR a 5-point increase from the baseline NPI score at the end of Phase A~A score of 6 (much worse) or 7 (very much worse) on the Clinical Global Impression-Change (CGI-C) at any visit." (NCT00417482)
Timeframe: 0-16 weeks in Phase B (16-32 weeks in study)
| Intervention | participants (Number) |
|---|---|
| Phase B Arm 1: Risperidone-Risperidone | 15 |
| Phase B Arm 2: Risperidone -Placebo | 8 |
| Phase B Arm 3: Placebo-Placebo | 24 |
Same definition and criteria as the primary outcome (NCT00417482)
Timeframe: 16-32 weeks in Phase B (32-48 weeks in study)
| Intervention | participants (Number) |
|---|---|
| Arm 1: Risperidone - Risperidone | 2 |
| Arm 2: Risperidone - Placebo | 13 |
The Treatment Emergent Symptom Scale (TESS) assesses 26 somatic symptoms. Total scores range from 0-26, with a score of 0 or 1 for each item. Higher scores indicate more somatic symptoms. For each subject, the change in TESS between week 16 and baseline (randomization) was calculated by subtraction, so that a positive value indicates an increase in TESS over time. (NCT00417482)
Timeframe: Phase B, weeks 1-16 (study weeks 16-32)
| Intervention | units on a scale (Mean) |
|---|---|
| Placebo | 0.18 |
| Risperidone | 0.21 |
For each subject, the change in weight in pounds between week 16 and randomization was calculated by subtraction, so that a positive value indicates an increase in weight over time. (NCT00417482)
Timeframe: Phase B, weeks 1-16 (study weeks 16-32)
| Intervention | pounds (Mean) |
|---|---|
| Placebo | 0.32 |
| Risperidone | 0.73 |
Basic Activities of Daily Living with items for 6 functions: bathing, dressing, toileting, transferring, continence, and feeding. Each item is scored as unimpaired=1, impaired=0. Total score is the measure used, range 0-6; higher scores indicate better functioning. (NCT02129348)
Timeframe: Assessed at Week 0, Week2, Week 4, Week 6, Week 8, Week 10, Week 12
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Lithium Treatment Group | 0.3 |
| Placebo Group | 0.1 |
Neuropsychiatric Inventory (NPI) Agitation/Aggression Domain is the measure used that combines symptoms of agitation and aggression. Frequency X Severity rating score, range 0-12. Higher score indicates more agitation and aggressive behavior. (NCT02129348)
Timeframe: Assessed at screening, Week 0, Week 2, Week 4, Week 6, Week 8, Week 10, Week 12
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Lithium Treatment Group | 3.2 |
| Placebo Group | 2.5 |
Clinical Global Impression (CGI) Behavior Change score is the measure used to assess change in overall behavior; scoring range 1-7 with higher scores indicating worsening over time and lower scores indicating improvement over time. Scores ranging from 1-3 indicate improvement. Only patients that demonstrated improvement at week 12 were reported; scores for earlier weeks were only used to assess progress throughout the study. (NCT02129348)
Timeframe: Week 12
| Intervention | Participants (Count of Participants) |
|---|---|
| Lithium Treatment Group | 12 |
| Placebo Group | 8 |
The patient is classified as a responder (score=1) if both criteria are met or as a non-responder (score=0) if both criteria are not met. The first criterion to determine responder status, NPI core score, has a scoring range 0-36; each of the three component scores for symptoms of agitation/aggression, delusions and hallucinations has a scoring range 0-12. For each symptom and the total score, higher score indicates more symptoms. The second criterion to determine responder status, Clinical Global Impression (CGI), is used to assess change in overall behavior; scoring range 1-7 with higher scores indicating worsening over time and lower scores indicating improvement over time. Only patients who met both criteria, assessed as change compared to baseline, were counted as responders; all other patients were non-responders. Patients that demonstrated improvement at week 12 were reported; scores for earlier weeks were only used to assess progress throughout the study. (NCT02129348)
Timeframe: Week 12
| Intervention | Participants (Count of Participants) |
|---|---|
| Lithium Treatment Group | 12 |
| Placebo Group | 7 |
30 item questionnaire used to assess degree of cognitive impairment. Orientation, registration, attention/calculation, recall, language, repetitions and commands are assessed. Total score is the measure used; range 0-30, higher scores indicate better global cognitive function. (NCT02129348)
Timeframe: Assessed at Screening, Week 12
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Lithium Treatment Group | 0.9 |
| Placebo Group | 0.9 |
Neuropsychological test used to assess a patient's cognitive ability. The patient is asked to complete small tasks such as drawing shapes and printing their name. They are also asked to remember certain names and objects, such as a cup and a spoon, and the evaluator's first name. Total score is the measure used; range 0-100, higher scores indicate better cognition. (NCT02129348)
Timeframe: Assessed at Week 0, Week 12
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Lithium Treatment Group | 2.1 |
| Placebo Group | -0.0 |
Simpson Angus Scale for Extrapyramidal Sign requires in-person examination to assess gait, arm dropping, shoulder shaking, elbow rigidity, wrist rigidity, leg pendulousness, head dropping, glabella tap, tremor, and salivation. Total score is the measure used, range 0-40; higher scores indicate increased severity of signs. (NCT02129348)
Timeframe: Assessed at Week 0, Week 2, Week 4, Week 6, Week 8, Week 10, Week 12
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Lithium Treatment Group | -0.0 |
| Placebo Group | 0.0 |
Treatment Emergent Symptom Scale that covers 26 somatic symptoms, each rated as present (score=1) or absent (score=0). Total score is the measure used with scoring range 0-26; higher scores indicate more somatic symptoms. (NCT02129348)
Timeframe: Assessed at Week 0, Week 2, Week 4, Week 6, Week 8, Week 10, Week 12
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Lithium Treatment Group | 0.6 |
| Placebo Group | 0.7 |
Young Mania Rating Scale total score is the measure used to assess symptoms that occur in mania; each item is a symptom that is rated for severity. Scoring range 0-60; higher scores indicate more severe symptoms. (NCT02129348)
Timeframe: Assessed at Week 0, Week 2, Week 4, Week 6, Week 8, Week 10, Week 12
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Lithium Treatment Group | 3.1 |
| Placebo Group | 1.1 |
Zarit Caregiver Burden Interview with the caregiver asked to rank 22 items on a scale with responses for each item from 'never' (score 0) to 'nearly always' (score 4). Total score is the measure used; range 0-88 with higher scores indicating greater caregiver burden. (NCT02129348)
Timeframe: Assessed at Week 0, Week 4, Week 8, Week 10, Week 12
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Lithium Treatment Group | 2.8 |
| Placebo Group | -0.4 |
"The Neuropsychiatric Inventory - Nursing Home Version (NPI-NH) test will characterize the neuropsychiatric and psychopathological symptoms of patients affected by dementia.~Events as delirium, anxiety, depression, etc. will be recorded by the frequency (from 0, absence, to 4, high frequency) and the seriousness (from 0, absence, to 3, high). The total score of the NPI-NH is given by the frequency x (multiply) seriousness (total score for each event has a range from 0 to 12). The patient final score will be given by the sum of the score of the 12 events. For each patient will be given a total score from 0 to 144.~NPI NH score has been collected in both control and aromatherapy groups at T1 and T3, in patients who needed and who did not needed Pro Re Nata." (NCT03662360)
Timeframe: Time 1 (baseline) and Time 3 (day 7)
| Intervention | score on a scale (Mean) | ||
|---|---|---|---|
| T1 NPI score in patients do not need Pro Re Nata | T3 NPI score in patients needed Pro Re Nata | T3 NPI score in patients do not need Pro Re Nata | |
| GROUP A - Control Group | 21.81 | 32.87 | 20.00 |
| GROUP B - Aromatherapy Group | 25.93 | 16.5 | 7.25 |
NPI-NH assess the psychological distress in physicians, nurses and nursing assistants who managed the patients. It has a score from 0 (no discomfort) to score of 5 (extreme discomfort). The psychological distress is measured for each of the 12 events in the NPI-NH scale, for a total score from 0 to 60. (NCT03662360)
Timeframe: Time 1 (baseline) and Time 3 (day 7)
| Intervention | score on a scale (Mean) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| T1 NPI NH physicians in pts with PRN | T1 NPI NH physicians in pts without PRN | T1 NPI NH nurses in pts with PRN | T1 NPI NH nurses in pts without PRN | T1 NPI NH nursing assistants in pts with PRN | T1 NPI NH nursing assistants in pts without PRN | T3 NPI NH physician in pts with PRN | T3 NPI NH physician in pts without PRN | T3 NPI NH nurses in pts with PRN | T3 NPI NH nurses in pts without PRN | T3 NPI NH nursing assistants in pts with PRN | T3 NPI NH nursing assistants in pts without PRN | |
| GROUP A - Control Group | 4.19 | 1.60 | 9.63 | 6.40 | 11.00 | 7.10 | 6.00 | 3.20 | 12.00 | 9.30 | 13.19 | 9.90 |
| GROUP B - Aromatherapy Group | 5.64 | 4.13 | 11.64 | 10.13 | 12.21 | 10.88 | 2.64 | 0.88 | 5.79 | 4.25 | 5.93 | 4.38 |
12 reviews available for risperidone and Acute Confusional Senile Dementia
| Article | Year |
|---|---|
Antipsychotics for agitation and psychosis in people with Alzheimer's disease and vascular dementia.
Topics: Alzheimer Disease; Antipsychotic Agents; Dementia, Vascular; Humans; Psychotic Disorders; Randomized | 2021 |
Antipsychotics for agitation and psychosis in people with Alzheimer's disease and vascular dementia.
Topics: Alzheimer Disease; Antipsychotic Agents; Dementia, Vascular; Humans; Psychotic Disorders; Randomized | 2021 |
Antipsychotics for agitation and psychosis in people with Alzheimer's disease and vascular dementia.
Topics: Alzheimer Disease; Antipsychotic Agents; Dementia, Vascular; Humans; Psychotic Disorders; Randomized | 2021 |
Antipsychotics for agitation and psychosis in people with Alzheimer's disease and vascular dementia.
Topics: Alzheimer Disease; Antipsychotic Agents; Dementia, Vascular; Humans; Psychotic Disorders; Randomized | 2021 |
Nose-to-brain drug delivery: An update on clinical challenges and progress towards approval of anti-Alzheimer drugs.
Topics: Administration, Intranasal; Alzheimer Disease; Animals; Biological Availability; Blood-Brain Barrier | 2018 |
Atypical antipsychotics in Parkinson-sensitive populations.
Topics: Alzheimer Disease; Antipsychotic Agents; Benzodiazepines; Clozapine; Dementia, Vascular; Dibenzothia | 2002 |
Pharmacologic management of psychosis in the elderly: a critical review.
Topics: Aged; Alzheimer Disease; Benzodiazepines; Bipolar Disorder; Clozapine; Depressive Disorder; Drug Adm | 2003 |
Dementia.
Topics: Alzheimer Disease; Antipsychotic Agents; Benzodiazepines; Cognition; Dementia; Donepezil; Galantamin | 2004 |
Management of agitation, aggression, and psychosis associated with dementia: a pooled analysis including three randomized, placebo-controlled double-blind trials in nursing home residents treated with risperidone.
Topics: Aged; Alzheimer Disease; Antipsychotic Agents; Basal Ganglia Diseases; Dementia, Vascular; Double-Bl | 2005 |
The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer's disease.
Topics: Aggression; Alzheimer Disease; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Dibenzothiazepin | 2006 |
The efficacy and safety of risperidone in the treatment of psychosis of Alzheimer's disease and mixed dementia: a meta-analysis of 4 placebo-controlled clinical trials.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antipsychotic Agents; Dementia; Double-Blind Method; Fem | 2007 |
Neuropsychiatric manifestations of diffuse Lewy body disease.
Topics: Alzheimer Disease; Antipsychotic Agents; Brain Stem; Clozapine; Dopamine Antagonists; Humans; Lewy B | 1995 |
Scales to assess efficacy and safety of pharmacologic agents in the treatment of behavioral and psychological symptoms of dementia.
Topics: Aged; Alzheimer Disease; Antipsychotic Agents; Basal Ganglia Diseases; Clinical Trials as Topic; Con | 2001 |
Underlying mechanisms of psychosis and aggression in patients with Alzheimer's disease.
Topics: Aged; Aggression; Alzheimer Disease; Antipsychotic Agents; Basal Ganglia Diseases; Humans; Multicent | 2001 |
Guidelines for managing Alzheimer's disease: Part II. Treatment.
Topics: Advance Directives; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Disease Progression; D | 2002 |
36 trials available for risperidone and Acute Confusional Senile Dementia
| Article | Year |
|---|---|
Guiding safer risperidone prescribing in Alzheimer's disease with therapeutic drug monitoring.
Topics: Alzheimer Disease; Antipsychotic Agents; Bayes Theorem; Drug Monitoring; Humans; Risperidone | 2023 |
Galantamine versus risperidone for agitation in people with dementia: a randomized, twelve-week, single-center study.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antipsychotic Agents; Dementia; Dementia, Vascular; Fema | 2014 |
Low-Dose Atypical Antipsychotic Risperidone Improves the 5-Year Outcome in Alzheimer's Disease Patients with Sleep Disturbances.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antipsychotic Agents; Caregivers; Donepezil; Female; Hum | 2015 |
Gray matter volumes and treatment response of psychotic symptoms to risperidone in antipsychotic-naïve Alzheimer's disease patients.
Topics: Aged; Alzheimer Disease; Amygdala; Antipsychotic Agents; Female; Gray Matter; Humans; Magnetic Reson | 2016 |
Lack of Early Improvement with Antipsychotics is a Marker for Subsequent Nonresponse in Behavioral and Psychological Symptoms of Dementia: Analysis of CATIE-AD Data.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antipsychotic Agents; Behavioral Symptoms; Benzodiazepin | 2017 |
Effects of Risperidone and Galantamine Treatment on Alzheimer's Disease Biomarker Levels in Cerebrospinal Fluid.
Topics: Aged; Alzheimer Disease; Amyloid beta-Peptides; Biomarkers; Cholinesterase Inhibitors; Follow-Up Stu | 2017 |
Clinical symptom responses to atypical antipsychotic medications in Alzheimer's disease: phase 1 outcomes from the CATIE-AD effectiveness trial.
Topics: Activities of Daily Living; Aged; Aggression; Alzheimer Disease; Antipsychotic Agents; Benzodiazepin | 2008 |
Metabolic changes associated with second-generation antipsychotic use in Alzheimer's disease patients: the CATIE-AD study.
Topics: Aged; Alzheimer Disease; Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Double-Blind Met | 2009 |
Comparison of topiramate and risperidone for the treatment of behavioral disturbances of patients with Alzheimer disease: a double-blind, randomized clinical trial.
Topics: Aged; Alzheimer Disease; Anticonvulsants; Antipsychotic Agents; Behavioral Symptoms; Caregivers; Dou | 2010 |
Association of 9-hydroxy risperidone concentrations with risk of switching or discontinuation in the clinical antipsychotic trial of intervention effectiveness-Alzheimer's disease trial.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antipsychotic Agents; Area Under Curve; Dose-Response Re | 2010 |
The antipsychotic discontinuation in Alzheimer disease trial: clinical rationale and study design.
Topics: Alzheimer Disease; Antipsychotic Agents; Clinical Protocols; Double-Blind Method; Humans; Psychomoto | 2012 |
Escitalopram versus risperidone for the treatment of behavioral and psychotic symptoms associated with Alzheimer's disease: a randomized double-blind pilot study.
Topics: Aged; Alzheimer Disease; Antipsychotic Agents; Citalopram; Double-Blind Method; Female; Humans; Male | 2011 |
Cognitive effects of atypical antipsychotic medications in patients with Alzheimer's disease: outcomes from CATIE-AD.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Antipsychotic Agents; Benzod | 2011 |
Relapse risk after discontinuation of risperidone in Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Aggression; Alzheimer Disease; Antipsychotic Agents; Double-Blind Method; F | 2012 |
Relapse risk after discontinuation of risperidone in Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Aggression; Alzheimer Disease; Antipsychotic Agents; Double-Blind Method; F | 2012 |
Relapse risk after discontinuation of risperidone in Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Aggression; Alzheimer Disease; Antipsychotic Agents; Double-Blind Method; F | 2012 |
Relapse risk after discontinuation of risperidone in Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Aggression; Alzheimer Disease; Antipsychotic Agents; Double-Blind Method; F | 2012 |
A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia.
Topics: Aged; Aggression; Alzheimer Disease; Antipsychotic Agents; Basal Ganglia Diseases; Dementia, Vascula | 2003 |
Risperidone use in Korean patients with Alzheimer's disease: optimal dosage and effect on behavioural and psychological symptoms, cognitive function and activities of daily living.
Topics: Activities of Daily Living; Aged; Alzheimer Disease; Antipsychotic Agents; Cognition; Dose-Response | 2003 |
Risperidone is effective for wandering and disturbed sleep/wake patterns in Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Aggression; Alzheimer Disease; Analysis of Variance; Antipsychotic Agents; | 2004 |
Comparison of the efficacy of new and conventional antipsychotic drugs in the treatment of behavioral and psychological symptoms of dementia (BPSD).
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antipsychotic Agents; Benzodiazepines; Brain; Diagnostic | 2004 |
Behavioral and psychological symptoms in patients with dementia as a target for pharmacotherapy with risperidone.
Topics: Aged; Aggression; Alzheimer Disease; Antipsychotic Agents; Dementia; Dementia, Vascular; Female; Hum | 2004 |
Psychometric performance of an assessment scale for strain in nursing care: the M-NCAS.
Topics: Aged; Aggression; Alzheimer Disease; Australia; Dementia, Vascular; Double-Blind Method; Female; Hum | 2004 |
Responsiveness of the quality of life in late-stage dementia scale to psychotropic drug treatment in late-stage dementia.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antipsychotic Agents; Benzodiazepines; Double-Blind Meth | 2005 |
Comparison of olanzapine and risperidone in the treatment of psychosis and associated behavioral disturbances in patients with dementia.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiaze | 2005 |
Risperidone for psychosis of Alzheimer's disease and mixed dementia: results of a double-blind, placebo-controlled trial.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antipsychotic Agents; Dementia, Vascular; Double-Blind M | 2005 |
Risperidone in the treatment of psychosis of Alzheimer disease: results from a prospective clinical trial.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antipsychotic Agents; Dose-Response Relationship, Drug; | 2006 |
Treating behavioral and psychological symptoms in patients with psychosis of Alzheimer's disease using risperidone.
Topics: Aged; Alzheimer Disease; Antipsychotic Agents; Double-Blind Method; Female; Humans; Male; Middle Age | 2007 |
Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Double-Blind Met | 2006 |
Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Double-Blind Met | 2006 |
Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Double-Blind Met | 2006 |
Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Double-Blind Met | 2006 |
Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Double-Blind Met | 2006 |
Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Double-Blind Met | 2006 |
Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Double-Blind Met | 2006 |
Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Double-Blind Met | 2006 |
Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Double-Blind Met | 2006 |
Amisulpride versus risperidone treatment for behavioral and psychological symptoms in patients with dementia of the Alzheimer type: a randomized, open, prospective study.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Amisulpride; Antipsychotic Agents; Behavioral Symptoms; | 2006 |
Risperidone and rivastigmine and agitated behaviour in severe Alzheimer's disease: a randomised double blind placebo controlled study.
Topics: Aged, 80 and over; Alzheimer Disease; Antipsychotic Agents; Cholinesterase Inhibitors; Dose-Response | 2007 |
Nursing home research from industry's perspective.
Topics: Aged; Alzheimer Disease; Antipsychotic Agents; Dementia; Dose-Response Relationship, Drug; Ethics, M | 1996 |
A structured trial of risperidone for the treatment of agitation in dementia.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Analysis of Variance; Antipsychotic Agents; Basal Gangli | 1998 |
Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. Risperidone Study Group.
Topics: Aged; Aged, 80 and over; Aggression; Alzheimer Disease; Antipsychotic Agents; Basal Ganglia Diseases | 1999 |
Low incidence of persistent tardive dyskinesia in elderly patients with dementia treated with risperidone.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antipsychotic Agents; Dementia; Dementia, Vascular; Dose | 2000 |
Efficacy and safety of risperidone oral solution in agitation associated with dementia in the elderly.
Topics: Administration, Oral; Aged; Alzheimer Disease; Antipsychotic Agents; Basal Ganglia Diseases; Dementi | 2001 |
National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): Alzheimer disease trial methodology.
Topics: Aged; Algorithms; Alzheimer Disease; Antipsychotic Agents; Benzodiazepines; Citalopram; Cost-Benefit | 2001 |
A double-blind randomised comparison of risperidone and haloperidol in the treatment of behavioural and psychological symptoms in Chinese dementia patients.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Dementia, Vascular; Double-Blind Method; Female; Haloper | 2001 |
Effect of risperidone on behavioral and psychological symptoms and cognitive function in dementia.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antipsychotic Agents; Basal Ganglia Diseases; Caregivers | 2001 |
78 other studies available for risperidone and Acute Confusional Senile Dementia
| Article | Year |
|---|---|
Antipsychotic Use and Risk of Stroke Among Community-Dwelling People With Alzheimer's Disease.
Topics: Alzheimer Disease; Antipsychotic Agents; Cohort Studies; Humans; Independent Living; Quetiapine Fuma | 2022 |
A comparative study of olanzapine, aripiprazole and risperidone in the treatment of psychiatric and behavioral symptoms of Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Antipsychotic Agents; Aripiprazole; Female; Humans; Male; Olanzapine; Retro | 2021 |
Neuropsychiatric Symptoms in Dementia: Considering a Clinical Role for Electroencephalography.
Topics: Alzheimer Disease; Dementia; Electroencephalography; Galantamine; Humans; Neuropsychological Tests; | 2022 |
Depicting Risperidone Safety Profiles in Clinical Trials Across Different Diagnoses Using a Dopamine D
Topics: Adolescent; Adult; Alzheimer Disease; Antipsychotic Agents; Bayes Theorem; Benzodiazepines; Dopamine | 2022 |
Accumulation of Hospital Days Among Antipsychotic Initiators With Alzheimer's Disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antipsychotic Agents; Cohort Studies; Female; Finland; F | 2019 |
[Antioxidant status in patients with paranoid schizophrenia and Alzheimer disease].
Topics: Alzheimer Disease; Antioxidants; Antipsychotic Agents; Clozapine; Humans; Risperidone; Schizophrenia | 2020 |
Towards safer risperidone prescribing in Alzheimer's disease.
Topics: Aggression; Alzheimer Disease; Antipsychotic Agents; Humans; Psychotic Disorders; Risperidone | 2021 |
Severe hypoglycemia in an elderly patient with Alzheimer's disease and with sepsis: The role of neurotransmitters on glucose regulation.
Topics: Aged, 80 and over; Alzheimer Disease; Blood Glucose; Dopamine; Dopamine Agents; Dopamine Antagonists | 2021 |
Anticholinergic Burden and Functional Status in Older People with Cognitive Impairment: Results from the Regal Project.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Cholinergic Antagonists; Cog | 2017 |
Hallucinations Predict Relapse After Discontinuation of Risperidone in Patients With Alzheimer's Disease and Psychosis or Agitation.
Topics: Alzheimer Disease; Antipsychotic Agents; Hallucinations; Humans; Psychomotor Agitation; Psychotic Di | 2017 |
Evaluation of the effects of anti-psychotic drugs on the expression of CD68 on the peripheral blood monocytes of Alzheimer patients with psychotic symptoms.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antigens, CD; Antigens, Differentiation, Myelomonocytic; | 2017 |
Screening approach for identifying candidate drugs and drug-drug interactions related to hip fracture risk in persons with Alzheimer disease.
Topics: Acetaminophen; Adult; Aged; Aged, 80 and over; Alzheimer Disease; Codeine; Cross-Over Studies; Drug | 2017 |
Marble-burying is enhanced in 3xTg-AD mice, can be reversed by risperidone and it is modulable by handling.
Topics: Alzheimer Disease; Animals; Antipsychotic Agents; Anxiety; Behavior, Animal; Disease Models, Animal; | 2015 |
Stooped Position in Elderly Patients With Alzheimer Disease.
Topics: Aged; Alzheimer Disease; Humans; Posture; Risperidone | 2015 |
Long-term use of antipsychotics among community-dwelling persons with Alzheimer׳s disease: A nationwide register-based study.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antipsychotic Agents; Cohort Studies; Female; Finland; F | 2015 |
Tiapride is more effective and causes fewer adverse effects than risperidone in the treatment of senile dementia.
Topics: Alzheimer Disease; Antipsychotic Agents; Humans; Risperidone; Tiapride Hydrochloride; Treatment Outc | 2016 |
Prediction of Relapse After Discontinuation of Antipsychotic Treatment in Alzheimer's Disease: The Role of Hallucinations.
Topics: Aged; Alzheimer Disease; Antipsychotic Agents; Female; Hallucinations; Humans; Intention to Treat An | 2017 |
Risperidone ameliorated Aβ
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid Precursor Protein Secretases; Animals; Apoptosis; | 2017 |
Antipsychotic Use and the Risk of Hip Fracture Among Community-Dwelling Persons With Alzheimer's Disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antipsychotic Agents; Cohort Studies; Cross-Sectional St | 2017 |
Validation of the APP23 transgenic mouse model of Alzheimer's disease through evaluation of risperidone treatment on aggressive behaviour.
Topics: Aggression; Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Antipsychotic Agents; Data I | 2008 |
Population pharmacokinetic analysis for risperidone using highly sparse sampling measurements from the CATIE study.
Topics: Adult; Age Factors; Aged; Alzheimer Disease; Antipsychotic Agents; Biological Availability; Body Wei | 2008 |
Using risperidone for Alzheimer's dementia-associated psychosis.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antipsychotic Agents; Humans; Psychotic Disorders; Rispe | 2008 |
[Antipsychotic treatment of dementia after publication of new risks].
Topics: Adverse Drug Reaction Reporting Systems; Aged; Alzheimer Disease; Antipsychotic Agents; Cerebral Inf | 2010 |
A perfect storm in the emergency department.
Topics: Aged; Alzheimer Disease; Citalopram; Drug Therapy, Combination; Female; Humans; Iatrogenic Disease; | 2010 |
Risperidone and dementia-related aggression: new indication. A last resort, no better than haloperidol.
Topics: Aged; Aggression; Alzheimer Disease; Antipsychotic Agents; Dementia; Drug Approval; Europe; France; | 2009 |
74-year-old woman with new-onset myoclonus.
Topics: Aged; Alzheimer Disease; Cyproheptadine; Diagnosis, Differential; Dopamine Antagonists; Dose-Respons | 2010 |
Use and misuse of antipsychotic drugs in patients with dementia in Alzheimer special care units.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Antidepressive Agents; Antip | 2009 |
Transient psychosis due to caregiver burden in a patient caring for severely demented spouses.
Topics: Alzheimer Disease; Antipsychotic Agents; Caregivers; Female; Humans; Middle Aged; Psychotic Disorder | 2012 |
[Longterm treatment with Risperidone in Alzheimer's disease? No justification for more "drug deaths" in nursing homes!].
Topics: Alzheimer Disease; Antipsychotic Agents; Female; Humans; Male; Psychomotor Agitation; Psychotic Diso | 2013 |
Discontinuation of risperidone in Alzheimer's disease.
Topics: Alzheimer Disease; Antipsychotic Agents; Female; Humans; Male; Psychomotor Agitation; Psychotic Diso | 2013 |
Discontinuation of risperidone in Alzheimer's disease.
Topics: Alzheimer Disease; Antipsychotic Agents; Female; Humans; Male; Psychomotor Agitation; Psychotic Diso | 2013 |
Discontinuation of risperidone in Alzheimer's disease.
Topics: Alzheimer Disease; Antipsychotic Agents; Female; Humans; Male; Psychomotor Agitation; Psychotic Diso | 2013 |
Discontinuation of risperidone in Alzheimer's disease.
Topics: Alzheimer Disease; Antipsychotic Agents; Female; Humans; Male; Psychomotor Agitation; Psychotic Diso | 2013 |
Extrapyramidal side-effect due to drug combination of risperidone and donepezil.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antipsychotic Agents; Basal Ganglia Diseases; Donepezil; | 2002 |
Re: Chan et al. A double-blind randomised comparison of risperidone and haloperidol in the treatment of behavioural and psychological symptoms in Chinese dementia patients. Int J Geriatr Psychiatry 16: 1156 - 1162.
Topics: Alzheimer Disease; Antipsychotic Agents; China; Double-Blind Method; Haloperidol; Humans; Mental Dis | 2002 |
[Effectiveness of rispolept in mental disorders in patients with Alzheimer and vascular types of dementia].
Topics: Aged; Alzheimer Disease; Antipsychotic Agents; Dementia, Vascular; Female; Humans; Male; Middle Aged | 2002 |
'Awakenings' in demented patients.
Topics: Aged; Alzheimer Disease; Antipsychotic Agents; Awareness; Cholinesterase Inhibitors; Delusions; Depr | 2003 |
Inpatient length of stay and atypical antipsychotic use among elderly patients with psychiatric disorders and Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antipsychotic Agents; Benzodiazepines; Cost Savings; Dib | 2003 |
Erotomania variants in dementia.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Bipolar Disorder; Delusions; Dementia, Vascular; Dopamin | 2003 |
Treatment of aggressive behavior in dementia with the anticonvulsant topiramate: a retrospective pilot study.
Topics: Aged; Aged, 80 and over; Aggression; Alzheimer Disease; Anticonvulsants; Antipsychotic Agents; Dose- | 2003 |
Risperidone in the treatment of elderly patients with psychosis of Alzheimer's disease and related dementias.
Topics: Aged; Alzheimer Disease; Antipsychotic Agents; Dementia; Double-Blind Method; Humans; Middle Aged; P | 2004 |
The management of psychogeriatric patient.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Aggression; Alzheimer Disease; Antipsychotic Ag | 2004 |
[Treatment of behavioral disorders in dementia with risperidone in psychogeriatric out-patients].
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Ambulatory Care; Antipsychotic Agents; Butyrophenones; C | 2003 |
[Cerebral infarct and atypical antipsychotic agents].
Topics: Aged; Alzheimer Disease; Antipsychotic Agents; Benzodiazepines; Cerebral Infarction; Dementia, Vascu | 2004 |
[Facilitating nursing at home and in the nursing home].
Topics: Aged; Alzheimer Disease; Antipsychotic Agents; Clinical Trials as Topic; Consensus Development Confe | 2005 |
Gonadotrophin-releasing hormone agonist treatment of aggression in Alzheimer's disease: a case report.
Topics: Aged; Aggression; Alzheimer Disease; Amines; Antipsychotic Agents; Benzodiazepines; Cyclohexanecarbo | 2005 |
Antipsychotic dose-sparing effect with addition of memantine.
Topics: Aged; Aggression; Alzheimer Disease; Antipsychotic Agents; Dopamine Agents; Drug Therapy, Combinatio | 2005 |
Effect of antipsychotics on mortality in elderly patients with dementia: a 1-year prospective study in a nursing home.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antipsychotic Agents; Confidence Intervals; Dementia, Va | 2005 |
Factor analysis of the Cohen-Mansfield Agitation Inventory in three large samples of nursing home patients with dementia and behavioral disturbance.
Topics: Aged; Aged, 80 and over; Aggression; Alzheimer Disease; Antipsychotic Agents; Cross-Sectional Studie | 2005 |
Psychosis of Alzheimer disease.
Topics: Aged; Alzheimer Disease; Antipsychotic Agents; Benzodiazepines; Cause of Death; Controlled Clinical | 2006 |
No effect of atypical antipsychotic drugs on weight gain and risk of developing type II diabetes or lipid abnormalities among nursing home elderly patients with Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Di | 2006 |
Clinical experience with risperidone in the treatment of behavioral and psychological symptoms of dementia.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antipsychotic Agents; Behavior; Female; Humans; Male; Mi | 2007 |
Long-acting injectable risperidone for control of agitation in dementia.
Topics: Aged; Alzheimer Disease; Delayed-Action Preparations; Female; Humans; Patient Compliance; Psychiatri | 2006 |
[Study questions the benefit of the treatment. Aggressive Alzheimer patient -- a (not a) case for atypical neuroleptics?].
Topics: Aggression; Alzheimer Disease; Antipsychotic Agents; Benzodiazepines; Controlled Clinical Trials as | 2006 |
The switching of risperidone to olanzapine in elderly nursing-home patients with dementia: a retrospective study.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Benzodiazepines; Comorbidity; Dementia, Vascular; Dose-R | 2007 |
Atypical antipsychotic agents ineffective for AD.
Topics: Alzheimer Disease; Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Humans; Olanzapine; Ps | 2007 |
The outpatient use of atypical antipsychotics with Alzheimer's disease.
Topics: Alzheimer Disease; Antipsychotic Agents; Benzodiazepines; Clinical Trials as Topic; Data Interpretat | 2007 |
[Efficacy of atypical antipsychotics in patients with Alzheimer's dementia. CATIE-AD-Study (Clinical Antipsychotic Trials of Intervention Effectiveness Alzheimer's Disease)].
Topics: Aged; Alzheimer Disease; Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Double-Blind Met | 2007 |
Behavioral and psychological symptoms assessed with the BEHAVE-AD-FW are differentially associated with cognitive dysfunction in Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antipsychotic Agents; Behavioral Symptoms; Cognition Dis | 2007 |
Effect of antipsychotic medication use on memory in patients with Alzheimer's disease: Assessing the potential risk for accelerated recent autobiographical memory loss.
Topics: Aged; Alzheimer Disease; Antipsychotic Agents; Autobiographies as Topic; Benzodiazepines; Dibenzothi | 2007 |
Atypical antipsychotics for the treatment of dementia-related behaviors: an update.
Topics: Aged; Alzheimer Disease; Antipsychotic Agents; Behavioral Symptoms; Benzodiazepines; Dementia; Diben | 2007 |
Comparison of risk of cerebrovascular events in an elderly VA population with dementia between antipsychotic and nonantipsychotic users.
Topics: Aged; Alzheimer Disease; Antipsychotic Agents; Benzodiazepines; Databases, Factual; Dementia, Vascul | 2007 |
Risperidone, olanzapine and quetiapine in the treatment of behavioral and psychological symptoms in patients with Alzheimer's disease: preliminary findings from a naturalistic, retrospective study.
Topics: Activities of Daily Living; Aged; Alzheimer Disease; Antipsychotic Agents; Behavior; Benzodiazepines | 2007 |
Agitated behavior relieved following treatment of cervical dystonia in dementia.
Topics: Alzheimer Disease; Botulinum Toxins; Chlorpromazine; Dystonia; Female; Humans; Isoxazoles; Middle Ag | 1995 |
Risperidone for treating dementia-associated aggression.
Topics: Aged; Aged, 80 and over; Aggression; Alzheimer Disease; Dementia; Dementia, Vascular; Female; Humans | 1995 |
Risperidone and tardive dyskinesia in organic psychosis.
Topics: Aged; Alzheimer Disease; Antipsychotic Agents; Dyskinesia, Drug-Induced; Humans; Male; Risperidone | 1998 |
[A study of neuroleptic malignant syndrome in the presenium and senium].
Topics: Aged; Alzheimer Disease; Antipsychotic Agents; Dementia, Vascular; Female; Haloperidol; Humans; Male | 1998 |
Extrapyramidal side effects in a patient treated with risperidone plus donepezil.
Topics: Aged; Alzheimer Disease; Antipsychotic Agents; Basal Ganglia Diseases; Cholinesterase Inhibitors; Co | 1998 |
Telephone support service helps keep schizophrenics on track.
Topics: Alzheimer Disease; Antipsychotic Agents; Counseling; Disease Management; Health Services Accessibili | 1997 |
Risperidone treatment of behavioral disturbances in outpatients with dementia.
Topics: Age Factors; Aged; Alzheimer Disease; Antipsychotic Agents; Basal Ganglia Diseases; Dose-Response Re | 1999 |
Treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Antipsychotic Agents; Haloperidol; Humans; Risperidone | 2000 |
Tardive dyskinesia in older patients.
Topics: Adult; Age Factors; Aged; Alzheimer Disease; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiaz | 2000 |
Relation between cholinesterase inhibitor and Pisa syndrome.
Topics: Aged; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Donepezil; Dopamine Antagonists; Dys | 2000 |
Risperidone in the treatment of patients with Alzheimer's disease with negative symptoms.
Topics: Affect; Aged; Aged, 80 and over; Alzheimer Disease; Antipsychotic Agents; Cognition; Female; Humans; | 2000 |
The effect of institutional fiscal stress on the use of atypical antipsychotic medications in the treatment of schizophrenia.
Topics: Alzheimer Disease; Antipsychotic Agents; Benzodiazepines; Budgets; Clozapine; Comorbidity; Depressiv | 2001 |
Shifting from haloperidol to risperidone for behavioral disturbances in dementia: safety, response predictors, and mood effects.
Topics: Activities of Daily Living; Affect; Aged; Alzheimer Disease; Antipsychotic Agents; Dementia, Vascula | 2002 |
Reducing the burden of caring for Alzheimer's disease through the amelioration of "delusions of theft" by drug therapy.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antipsychotic Agents; Caregivers; Cost of Illness; Delus | 2002 |
[Atypical neuroleptics in dementia. Managing behavioral disorders early and efficiently].
Topics: Activities of Daily Living; Aged; Alzheimer Disease; Antipsychotic Agents; Butyrophenones; Clinical | 2002 |